# LEV102 Topical Gel in Acquired Blepharoptosis

> **NCT05715346** · PHASE1,PHASE2 · COMPLETED · sponsor: **Levation Pharma, Ltd.** · enrollment: 33 (actual)

## Conditions studied

- Acquired Blepharoptosis

## Interventions

- **DRUG:** LEV102 1.0%
- **DRUG:** LEV102 2.0%
- **DRUG:** Vehicle

## Key facts

- **NCT ID:** NCT05715346
- **Lead sponsor:** Levation Pharma, Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-02-23
- **Primary completion:** 2023-06-24
- **Final completion:** 2023-06-24
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2024-11-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05715346

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05715346, "LEV102 Topical Gel in Acquired Blepharoptosis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05715346. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*